The FDA has approved Zepatier for the treatment of HCV genotypes 1 and 4 infections. Zepatier has been approved by the FDA to treat hepatitis C virus genotypes 1 and 4 infections in adult patients.

In previous articles of this series, we’ve discussed several aspects of the hepatitis C virus including the nature of the infection and its distribution both globally and in the United States. Most ...

Epclusa (sofosbuvir/velpatasvir) is a brand-name prescription medication. It’s approved by the Food and Drug Administration (FDA) to treat hepatitis C, which is an ...

The World Health Organization currently estimates the global burden of Hepatitis C to be between 130 and 170 million people. Ideally, this figure, as well as stratifications by location, age, and ...

Hepatitis is an inflamed liver.One of the more common causes is a virus called hepatitis C, or "hep C". It is now curable. SVR stands for sustained virologic response. It means that 12 weeks or more ...

In this real‑world multicenter study (Wenzhou, China), 113 chronic hepatitis C patients received colbopasvir (60 mg) + ...

Rates of hepatitis C virus (HCV) treatment in a commercially insured population doubled after availability of new direct-acting antivirals. Member out-of-pocket spending was kept low while the health ...

A research team from Indonesia identified the distribution of hepatitis B virus subgenotype and basal core promoter mutations among patients with HBV-associated liver disease in Indonesia. They found ...